Stemline Therapeutics, Inc. (NASDAQ:STML) Upgraded at BidaskClub

Stemline Therapeutics, Inc. (NASDAQ:STML) was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating in a research report issued on Wednesday, July 19th.

Several other brokerages also recently commented on STML. Zacks Investment Research downgraded Stemline Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, July 18th. Cowen and Company reissued a “buy” rating on shares of Stemline Therapeutics in a research note on Thursday, March 23rd. HC Wainwright reissued a “buy” rating on shares of Stemline Therapeutics in a research note on Monday, May 15th. Wedbush reissued an “outperform” rating and issued a $11.00 price objective on shares of Stemline Therapeutics in a research note on Saturday, March 25th. Finally, Jefferies Group LLC reissued a “buy” rating and issued a $16.00 price objective on shares of Stemline Therapeutics in a research note on Thursday, May 25th. Two investment analysts have rated the stock with a sell rating and seven have issued a buy rating to the company’s stock. Stemline Therapeutics currently has a consensus rating of “Buy” and an average price target of $29.17.

Stemline Therapeutics (NASDAQ:STML) traded down 3.12% during mid-day trading on Wednesday, hitting $7.75. 176,032 shares of the stock were exchanged. Stemline Therapeutics has a one year low of $5.50 and a one year high of $14.60. The company’s market cap is $181.78 million. The company has a 50-day moving average price of $9.33 and a 200-day moving average price of $8.51.

Stemline Therapeutics (NASDAQ:STML) last announced its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.66) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.48) by $0.18. The company had revenue of $0.30 million for the quarter, compared to analyst estimates of $0.30 million. Stemline Therapeutics had a negative return on equity of 67.35% and a negative net margin of 4,176.84%. On average, analysts predict that Stemline Therapeutics will post ($2.44) earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This piece of content was published by BNB Daily and is the property of of BNB Daily. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States and international copyright law. The correct version of this piece of content can be read at https://www.baseball-news-blog.com/2017/08/13/stemline-therapeutics-inc-nasdaqstml-lifted-to-buy-at-bidaskclub-updated-updated-updated.html.

Hedge funds have recently modified their holdings of the company. Dimensional Fund Advisors LP raised its stake in shares of Stemline Therapeutics by 74.9% in the second quarter. Dimensional Fund Advisors LP now owns 120,477 shares of the biopharmaceutical company’s stock worth $1,108,000 after buying an additional 51,578 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Stemline Therapeutics by 4.7% in the second quarter. Vanguard Group Inc. now owns 863,768 shares of the biopharmaceutical company’s stock worth $7,946,000 after buying an additional 38,615 shares in the last quarter. Northern Trust Corp raised its stake in shares of Stemline Therapeutics by 18.0% in the second quarter. Northern Trust Corp now owns 274,824 shares of the biopharmaceutical company’s stock worth $2,529,000 after buying an additional 41,898 shares in the last quarter. Artal Group S.A. raised its stake in shares of Stemline Therapeutics by 150.0% in the second quarter. Artal Group S.A. now owns 250,000 shares of the biopharmaceutical company’s stock worth $2,300,000 after buying an additional 150,000 shares in the last quarter. Finally, Nationwide Fund Advisors raised its stake in shares of Stemline Therapeutics by 7.2% in the second quarter. Nationwide Fund Advisors now owns 12,755 shares of the biopharmaceutical company’s stock worth $117,000 after buying an additional 855 shares in the last quarter. 53.99% of the stock is owned by hedge funds and other institutional investors.

Stemline Therapeutics Company Profile

Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.

Analyst Recommendations for Stemline Therapeutics (NASDAQ:STML)

Receive News & Ratings for Stemline Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply